RDX

Across TCGA pan-cancer cohorts, RDX mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RDX data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RDX mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RDX expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where RDX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.374	0.710	<.001	56	view →
CCRCC	DFS	Median	III,IV	0.985	0.144	.008	32	view →
GBM	DFS	Tertile	All	0.576	0.804	.002	19	view →
HNSC	OS	Tertile	All	0.911	0.642	.003	17	view →
LSCC	DFS	Tertile	III,IV	0.416	1.000	.013	10	view →
LUAD	OS	Median	All	0.940	0.667	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RDX–PDAC (OS)

Open the PDAC breakdown →